Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Liraglutide Effect and Action in Diabetes (LEAD-2): Effect on Glycaemic Control After Once Daily Administration of Liraglutide in Combination With Metformin Versus Metformin Monotherapy Versus Metformin and Glimepiride Combination Therapy in Subjects With Type 2 Diabetes
Brief Summary: This trial is conducted in Europe, Oceania, Africa, Asia and South America. This trial is designed to show the effect of treatment with liraglutide when adding to existing metformin therapy and to compare it with the effects of metformin monotherapy and combination therapy of metformin and glimepiride. Two trial periods: A 6 month (26 weeks) randomised, double-blinded period followed by an 18 months open-label extension, in total 2 years (104 weeks).


Options:
A: Arm Label: Lira 0.6 + Met; Type: EXPERIMENTAL; Interventions: Drug: liraglutide, Drug: metformin, Drug: placebo | Arm Label: Lira 1.2 + Met; Type: EXPERIMENTAL; Interventions: Drug: metformin, Drug: placebo, Drug: liraglutide | Arm Label: Lira 1.8 + Met; Type: EXPERIMENTAL; Interventions: Drug: metformin, Drug: placebo, Drug: liraglutide | Arm Label: Met Mono; Type: ACTIVE_COMPARATOR; Interventions: Drug: metformin, Drug: placebo | Arm Label: Met + Glim; Type: ACTIVE_COMPARATOR; Interventions: Drug: metformin, Drug: glimepiride, Drug: placebo | Intervention Type: DRUG; Name: liraglutide; Assigned to Arm(s): Lira 0.6 + Met | Intervention Type: DRUG; Name: metformin; Assigned to Arm(s): Lira 0.6 + Met, Lira 1.2 + Met, Lira 1.8 + Met, Met + Glim, Met Mono | Intervention Type: DRUG; Name: glimepiride; Assigned to Arm(s): Met + Glim | Intervention Type: DRUG; Name: placebo; Assigned to Arm(s): Lira 0.6 + Met, Lira 1.2 + Met, Lira 1.8 + Met, Met Mono | Intervention Type: DRUG; Name: placebo; Assigned to Arm(s): Met + Glim, Met Mono | Intervention Type: DRUG; Name: liraglutide; Assigned to Arm(s): Lira 1.2 + Met | Intervention Type: DRUG; Name: liraglutide; Assigned to Arm(s): Lira 1.8 + Met
B: Arm Label: 1; Type: EXPERIMENTAL; Interventions: Drug: exenatide once weekly, Drug: placebo tablet | Arm Label: 2; Type: ACTIVE_COMPARATOR; Interventions: Drug: sitagliptin, Drug: placebo once weekly | Arm Label: 3; Type: ACTIVE_COMPARATOR; Interventions: Drug: pioglitazone, Drug: placebo once weekly | Intervention Type: DRUG; Name: exenatide once weekly; Assigned to Arm(s): 1 | Intervention Type: DRUG; Name: sitagliptin; Assigned to Arm(s): 2 | Intervention Type: DRUG; Name: pioglitazone; Assigned to Arm(s): 3 | Intervention Type: DRUG; Name: placebo tablet; Assigned to Arm(s): 1 | Intervention Type: DRUG; Name: placebo once weekly; Assigned to Arm(s): 2, 3
C: Arm Label: Sequence 1; Type: EXPERIMENTAL; Interventions: Drug: Exenatide - Exenatide - Placebo | Arm Label: Sequence 2; Type: EXPERIMENTAL; Interventions: Drug: Exenatide - Placebo - Exenatide | Arm Label: Sequence 3; Type: EXPERIMENTAL; Interventions: Drug: Placebo - Exenatide - Exenatide | Intervention Type: DRUG; Name: Exenatide - Exenatide - Placebo; Assigned to Arm(s): Sequence 1 | Intervention Type: DRUG; Name: Exenatide - Placebo - Exenatide; Assigned to Arm(s): Sequence 2 | Intervention Type: DRUG; Name: Placebo - Exenatide - Exenatide; Assigned to Arm(s): Sequence 3
D: Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo | Arm Label: Taspoglutide 20mg; Type: EXPERIMENTAL; Interventions: Drug: Taspoglutide 20mg | Arm Label: Taspoglutide 20mg-30mg; Type: EXPERIMENTAL; Interventions: Drug: Taspoglutide 20mg-30mg | Arm Label: Taspoglutide 20mg-40mg; Type: EXPERIMENTAL; Interventions: Drug: Taspoglutide 20mg-40mg | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): Placebo | Intervention Type: DRUG; Name: Taspoglutide 20mg; Assigned to Arm(s): Taspoglutide 20mg | Intervention Type: DRUG; Name: Taspoglutide 20mg-30mg; Assigned to Arm(s): Taspoglutide 20mg-30mg | Intervention Type: DRUG; Name: Taspoglutide 20mg-40mg; Assigned to Arm(s): Taspoglutide 20mg-40mg

Answer: A